Dianthus Therapeutics Stock Market Outlook
| DNTH Stock | 47.43 0.03 0.06% |
Under 58% of Dianthus Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Dianthus Therapeutics suggests that many traders are alarmed. Dianthus Therapeutics' investing sentiment shows overall attitude of investors towards Dianthus Therapeutics.
Comfort Level 42
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Dianthus Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Dianthus Therapeutics.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Dianthus Therapeutics is 'Cautious Hold'. The recommendation algorithm takes into account all of Dianthus Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Execute Dianthus Therapeutics Advice
The Dianthus recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Dianthus Therapeutics. Macroaxis does not own or have any residual interests in Dianthus Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Dianthus Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Mild | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Moderate | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
For the selected time horizon Dianthus Therapeutics has a Mean Deviation of 2.97, Semi Deviation of 2.82, Standard Deviation of 4.31, Variance of 18.59, Downside Variance of 10.47 and Semi Variance of 7.94Our investment recommendation tool can be used to complement Dianthus Therapeutics trade advice provided by experts. It analyzes the company's potential to grow against your specific risk preferences and investment horizon. To make sure Dianthus Therapeutics is not overpriced, please confirm all Dianthus Therapeutics fundamentals, including its shares owned by insiders, book value per share, working capital, as well as the relationship between the revenue and number of employees . Given that Dianthus Therapeutics has a shares owned by institutions of 96.70 %, we urge you to verify Dianthus Therapeutics market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Dianthus Therapeutics Trading Alerts and Improvement Suggestions
| Dianthus Therapeutics had very high historical volatility over the last 90 days | |
| Dianthus Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 3.08 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: How Investors Are Reacting To Dianthus Therapeutics US600 Million Universal Shelf Registration |
Dianthus Therapeutics Returns Distribution Density
The distribution of Dianthus Therapeutics' historical returns is an attempt to chart the uncertainty of Dianthus Therapeutics' future price movements. The chart of the probability distribution of Dianthus Therapeutics daily returns describes the distribution of returns around its average expected value. We use Dianthus Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Dianthus Therapeutics returns is essential to provide solid investment analysis for Dianthus Therapeutics.
| Mean Return | 0.48 | Value At Risk | -4.95 | Potential Upside | 8.95 | Standard Deviation | 4.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Dianthus Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Dianthus Therapeutics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 73.5M | 7.8M | 117.0M | (109.4M) | (98.4M) | (93.5M) | |
| Free Cash Flow | (60.8M) | (29.2M) | (37.0M) | (78.3M) | (70.5M) | (74.0M) | |
| Depreciation | 2.0M | 147K | 355K | 412K | 473.8K | 450.1K | |
| Other Non Cash Items | 11.1M | (606K) | (762K) | (6.2M) | (5.5M) | (5.3M) | |
| Net Income | (71.1M) | (28.5M) | (43.6M) | (85.0M) | (76.5M) | (80.3M) | |
| End Period Cash Flow | 131.7M | 15.4M | 132.4M | 23.0M | 26.5M | 25.2M |
Dianthus Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Dianthus Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Dianthus Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Dianthus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.46 | |
β | Beta against Dow Jones | 0.25 | |
σ | Overall volatility | 3.76 | |
Ir | Information ratio | 0.1 |
Dianthus Therapeutics Volatility Alert
Dianthus Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Dianthus Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Dianthus Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Dianthus Therapeutics Fundamentals Vs Peers
Comparing Dianthus Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Dianthus Therapeutics' direct or indirect competition across all of the common fundamentals between Dianthus Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Dianthus Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Dianthus Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Dianthus Therapeutics to competition |
| Fundamentals | Dianthus Therapeutics | Peer Average |
| Return On Equity | -0.29 | -0.31 |
| Return On Asset | -0.19 | -0.14 |
| Operating Margin | (101.74) % | (5.51) % |
| Current Valuation | 1.65 B | 16.62 B |
| Shares Outstanding | 43.22 M | 571.82 M |
| Shares Owned By Insiders | 3.30 % | 10.09 % |
| Shares Owned By Institutions | 96.70 % | 39.21 % |
| Number Of Shares Shorted | 8.3 M | 4.71 M |
| Price To Book | 3.75 X | 9.51 X |
| Price To Sales | 665.62 X | 11.42 X |
| Revenue | 6.24 M | 9.43 B |
| Gross Profit | 3.08 M | 27.38 B |
| EBITDA | (101.45 M) | 3.9 B |
| Net Income | (84.97 M) | 570.98 M |
| Total Debt | 1.49 M | 5.32 B |
| Book Value Per Share | 12.75 X | 1.93 K |
| Cash Flow From Operations | (78.18 M) | 971.22 M |
| Short Ratio | 9.24 X | 4.00 X |
| Earnings Per Share | (3.50) X | 3.12 X |
| Target Price | 73.0 | |
| Number Of Employees | 78 | 18.84 K |
| Beta | 1.23 | -0.15 |
| Market Capitalization | 2.05 B | 19.03 B |
| Total Asset | 374.01 M | 29.47 B |
| Retained Earnings | (174.39 M) | 9.33 B |
| Working Capital | 262.45 M | 1.48 B |
| Net Asset | 374.01 M |
Note: Acquisition by Edward Carr of 55000 shares of Dianthus Therapeutics at 52.46 subject to Rule 16b-3 [view details]
Dianthus Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Dianthus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Dianthus Therapeutics Target Price Consensus
Dianthus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Dianthus Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Dianthus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Dianthus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Dianthus Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDianthus Therapeutics Target Price Projection
Dianthus Therapeutics' current and average target prices are 47.43 and 73.00, respectively. The current price of Dianthus Therapeutics is the price at which Dianthus Therapeutics is currently trading. On the other hand, Dianthus Therapeutics' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Dianthus Therapeutics Market Quote on 16th of February 2026
Target Price
Analyst Consensus On Dianthus Therapeutics Target Price
Dianthus Therapeutics Analyst Ratings
Dianthus Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Dianthus Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Dianthus Therapeutics' financials, market performance, and future outlook by experienced professionals. Dianthus Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Dianthus Therapeutics Buy or Sell Advice
When is the right time to buy or sell Dianthus Therapeutics? Buying financial instruments such as Dianthus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Dianthus Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beers Thematic Idea Now
Beers
Companies involved in production and distribution of domestic and international beer. The Beers theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Dianthus Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is there potential for Biotechnology market expansion? Will Dianthus introduce new products? Factors like these will boost the valuation of Dianthus Therapeutics. Projected growth potential of Dianthus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.50) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dianthus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dianthus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dianthus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.